CBPE sells Rosemont Pharmaceuticals to Perrigo

CBPE acquired the company for £93m in August 2006, providing £52m in equity. The exit represents a 3.25x multiple on the equity investment.

The selling price was $283m, according to reports. Perrigo is an American pharma company, listed on NASDAQ. Its market-cap lies at $10.3bn.

Company
Rosemont is a Leeds-based supplier of oral liquid medicine. Its product range includes 94 medicines. The company's EBITDA amounted to £19.2m in 2012 and it employs 209 staff.

The company's client base ranges from hospitals to wholesalers and retail pharmacies.

People
Partner Sean Dinnen led the original investment on behalf of CBPE. John Blythe is CEO of Rosemont.

Advisers
Vendor – Rothschild (Corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• UK / Ireland
• Healthcare
• United Kingdom
• United States
• Close Brothers Private Equity (CBPE)
• NASDAQ